MetrioPharm's MP1000 platform of small-molecule immune modulators targets signaling pathways that are common in the pathogenesis of all Immune-Mediated Inflammatory Diseases (IMIDs). This allows the design of drugs which have the potential to be therapeutically active in several IMIDs.

Our lead substance MP1032 belongs to this category. Other compounds from our MP1000 platform are designed to target specifically defined individual IMIDs.

Clinical development strategy

MetrioPharm follows a structured clinical development path, geared to further validate the outstanding safety of our MP1000 platform as well as their clinical efficacy.
The clinical development program currently focuses on the oral use of our lead product MP1032 for the treatment of chronic Immune-Mediated Inflammatory Diseases, with psoriasis as the model for these types of indications.
In parallel we also explore the efficacy of MP1032 in the treatment of tendinopathy as a model for acute-to-subchronic inflammatory conditions following i.e. injuries.
In both the treatment of chronic immune-Mediated inflammation and acute injury-Mediated inflammation there is a substantial unmet medical need and market opportunity for safe, well tolerated, and orally available therapies.


Psoriasis is an autoimmune disease and one of the most widely occurring IMIDs. The disease is characterized by scaling, reddening and itching of the skin in different areas of the body. Most affected are the scalp, elbows and knees.

Worldwide, more than 100 million people suffer from psoriasis, with 7 million in Europe and 7.5 million in the USA. With the advent of new and better treatments, the market for psoriasis drugs is expected to double from currently UDS 5 billion to about USD 10 billion within the next ten years.

Even though this disease is not directly life threatening, patients suffer profoundly from scaling and itching of the skin as well as from the appearance of psoriasis plaques, especially in exposed parts of the body.
This leads to a high incidence of depression and obesity, and a significantly increased risk for arthritis, diabetes, and other immune-Mediated inflammatory diseases. In addition, patients with moderate-to-severe psoriasis often have to take life-long medication, which in turn can bring serious side effects.
This results in a reduction of life expectancy of five to ten years.

In 2014, the World Health Organisation (WHO) therefore added psoriasis to the list of the five major, especially to support non-infectious diseases in the world - in addition to cancer, diabetes, heart and respiratory diseases.


Tendinopathy is a common term for tendinitis (inflammation of tendons) and tendinosis (injury of tendons).
Small internal micro-ruptures often occur when tendons around a joint are suddenly strained or over-used. Concomitantly a painful inflammation of the injured tendon (tendinitis) usually occurs.

Under normal circumstances and at younger age such injuries can heal from within days to several weeks. However, with increasing age or with continuing strain on the effected tendon a chronic inflammation often develops. The driving mechanism behind this continued inflammation are activated macrophages, which perpetuate the process and can lead to continued pain and lasting damage of the affected tendon.
Clinically this manifests as pain when moving the affected joint, decrease in movement range and eventually instability of the joint with lasting impairment.

Currently there is no effective drug to treat the underlying immune-driven inflammatory mechanism behind tendinopathy. Drug treatment is limited to analgesics, mostly NSAIDs (Non-steroidal Anti Inflammatory Drugs like Diclofenac and Ibuprofen) or steroids.

These drugs are effective to mitigate the pain but they do not aid in the healing process of the tendon – rather the opposite. MP1032's mechanism of action allows a new drug therapy approach. Instead of the usual pure pain treatment, a curative drug therapy of tendinopathy is now possible with MP1032.